1995
DOI: 10.1016/0006-3223(95)00178-8
|View full text |Cite
|
Sign up to set email alerts
|

Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

5
103
0

Year Published

2000
2000
2017
2017

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 157 publications
(108 citation statements)
references
References 11 publications
5
103
0
Order By: Relevance
“…All of these 10 trials were captured by our search method and are included in online supplementary Table 3 (references [27,28,29,30,31]) and in online supplementary Table 6 (references [32,33,34,35,36]). In accordance with the overall conclusion of this systematic review, these 10 studies also demonstrated superior responsiveness of HAM-D 6 compared to that of HAM-D 17 and MADRS.…”
Section: Resultsmentioning
confidence: 99%
“…All of these 10 trials were captured by our search method and are included in online supplementary Table 3 (references [27,28,29,30,31]) and in online supplementary Table 6 (references [32,33,34,35,36]). In accordance with the overall conclusion of this systematic review, these 10 studies also demonstrated superior responsiveness of HAM-D 6 compared to that of HAM-D 17 and MADRS.…”
Section: Resultsmentioning
confidence: 99%
“…The exclusion from the study of patients with primary affective illness or anxiety disorder diagnoses may have reduced the incidence of comorbid affective illness in the current sample compared with what has been reported in the community. 1 A potential therapeutic advantage of sertraline as a treatment for PTSD is its established efficacy in treating disorders commonly comorbid with PTSD, such as depression [31][32][33] and panic disorder. [34][35][36] In the current study, sertraline demonstrated a significant efficacy advantage over placebo in the treatment of PTSD (Table 3), although specific measures of panic or anxiety disorders were not obtained.…”
Section: Commentmentioning
confidence: 99%
“…Bupropion hydrochloride sustained release (SR) and sertraline have demonstrated antidepressant efficacy in randomized, double-blind, placebo-controlled studies in outpatients with major depressive disorder (Reimherr et al 1990(Reimherr et al , 1998Fabre et al 1995;Croft et al 1999;Coleman et al 1999). Bupropion has demonstrated comparable antidepressant efficacy to sertraline (Kavoussi et al 1997;Croft et al 1999;Coleman et al 1999), fluoxetine (Feighner et al 1991), and paroxetine (Weihs et al 2000) in outpatients with major depressive disorder.…”
mentioning
confidence: 99%